Transdermal pharmaceutical preparation containing active substance combinations, for treating Parkinson's disease
First Claim
1. A transdermal pharmaceutical preparation for the treatment of Parkinson'"'"'s disease containing a combination of two active substances, wherein said pharmaceutical preparation is a transdermal therapeutic system in the form of an active substance patch adhering to the skin, and the transdermal therapeutic patch contains said combination in a solid polymer matrix, and wherein said pharmaceutical preparation contains a combination of L-dopa and an anticholinergically active substance, said anticholinergically active substance being selected from the group consisting of bornaprine and metixene;
- and wherein said transdermal therapeutic system comprises different layers for containing said combination of two active substances, and wherein said two active substances of the active substance combination are contained in said different layers of the transdermal therapeutic system.
1 Assignment
0 Petitions
Accused Products
Abstract
The transdermal pharmaceutical preparations for the treatment of Parkinson'"'"'s disease contain a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics; at least two of the said active substances being members of different active substance groups.
26 Citations
11 Claims
-
1. A transdermal pharmaceutical preparation for the treatment of Parkinson'"'"'s disease containing a combination of two active substances, wherein said pharmaceutical preparation is a transdermal therapeutic system in the form of an active substance patch adhering to the skin, and the transdermal therapeutic patch contains said combination in a solid polymer matrix, and wherein said pharmaceutical preparation contains a combination of L-dopa and an anticholinergically active substance, said anticholinergically active substance being selected from the group consisting of bornaprine and metixene;
- and wherein said transdermal therapeutic system comprises different layers for containing said combination of two active substances, and wherein said two active substances of the active substance combination are contained in said different layers of the transdermal therapeutic system.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
11. A transdermal pharmaceutical preparation for the treatment of Parkinson'"'"'s disease containing a combination of two active substances, wherein said pharmaceutical preparation is a transdermal therapeutic system in the form of an active substance patch adhering to the skin, and the transdermal therapeutic patch contains said combination in a solid polymer matrix, and wherein said pharmaceutical preparation contains a combination of L-dopa and an anticholinergically active substance, said anticholinergically active substance being selected from the group consisting of bornaprine and metixene;
- and wherein said transdermal therapeutic system comprises at least two layers for containing said combination of two active substances, and wherein said two active substances of the active substance combination are contained in said at least two layers of the transdermal therapeutic system.
Specification